Skip to contentV
Viridian Therapeutics, Inc.
V
VRDNViridian Therapeutics, Inc. Q1 2023 · 10-Q
Revenue$98.00K$98.00K−54.6% vs Q1 2022 Net Income-$68.15M-$68.15MN/M vs Q1 2022 EPS Diluted-$1.61-$1.61N/M vs Q1 2022 Operating Income-$72,473,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Viridian Therapeutics, Inc. · CIK 1590750 · Engraved from SEC EDGAR
Free Cash Flowderived-$62,088,000N/M Margins · derivedOperating margin-73952.0%−61966.4 pt vs Q1 2022
Net margin-69541.8%−57646.9 pt vs Q1 2022
ended Mar 31, 2023 · filed May 10, 2023 · 40 d after period end